According to the findings, OR502 showed a safety profile without any adverse events reported even at the maximum dose level.

Nanoparticle-directed therapy has shown significant promise for treating localised prostate cancer, achieving tumour ablation ...

LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority ...

The largest trial of its kind in the U.K. has shown how a low-cost, structured, anti-bullying program can improve social ...

‘The effects and costs of an anti-bullying programme (KiVa) in UK primary schools: a multicentre cluster randomised ...

In January 2024, LumiThera commenced the EUROLIGHT study for individuals with AMD. The multicentre clinical registry study ...

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to ...

Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, into Phase III trials for treating MASH ...

This is needed as the optimal treatment for shoulder pain remains unclear.9 The objective of this multicentre longitudinal cohort study was to identity which patient and clinical characteristics, ...

The following is a summary of “Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year ...

The following is a summary of “Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open label, randomized, ...

Participants were survivors of acute ischemic strokes likely related to their Afib. In the hospital stroke unit, they were ...